---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000048"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-06-16T20:34:58+00:00"
generated_at: "2026-06-16T20:37:12.376415+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Travere CRO William Rote to retire Feb 2027; CMO Inrig promoted to EVP, Head of R&D

## Summary
- William Rote, Ph.D., Chief Research Officer, to retire effective Feb 17, 2027, after 10 years.
- Jula Inrig, M.D., current Chief Medical Officer, will assume Rote's responsibilities.
- Effective July 1, 2026, Dr. Inrig becomes EVP, Head of R&D and Chief Medical Officer.
- Travere expects to enter into a consulting arrangement with Dr. Rote post-retirement.

## SEC filing metadata
- accession: 0001438533-26-000048
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-06-16T20:34:58+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/tvtx-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000048
- JSON: https://secwatch.observer/filing/0001438533-26-000048.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000048.txt

## Key facts
- Executive change
  Jula Inrig was named as Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics, Inc..
  - Action: named
  - Role: Executive Vice President, Head of Research & Development and Chief Medical Officer
  source text: Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm
- Executive change
  William Rote departed as Chief Research Officer at Travere Therapeutics, Inc..
  - Action: retire
  - Role: Chief Research Officer
  source text: On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000048/0001438533-26-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.